The initial concept of human gene therapy was permanent correction of a recessive disease by transplantation of ex vivo manipulated stem cells (1) . An early and still important model for this strategy is treatment of severe combined immunodeficiency due to adenosine deaminase deficiency by bone marrowdirected gene therapy (2) . The autosomal recessive disease cystic fibrosis (CF)' was subsequently considered a candidate for gene therapy when the gene responsible for the disease was isolated in 1989 (3) (4) (5) . The wide distribution of possible cellular targets for gene transfer in the CF lung and the absence of a known lung epithelial stem cell suggested that an ex vivo approach to gene therapy would not be feasible (6, 7) . Research immediately focused on in vivo approaches for gene transfer that could conveniently be delivered into the airway via aerosols. The ensuing research effort has literally dominated the field of human gene therapy of genetic diseases while establishing the basic principles of in vivo gene delivery. This review summarizes critical scientific issues that have emerged in the development of in vivo gene therapy for CF using adenoviral vectors as a model. The CF conundrum: relationship between defective ion transport and lung disease CF is an autosomal recessive disease affecting many organs.
The pulmonary manifestations of CF are the most morbid and life-limiting aspects of the disease and, therefore, have been the target of most pharmacologic and genetic therapeutic interventions (8) . Autopsy analysis of newborn CF patients who died of meconium ileus suggests that the lung is largely unaffected at birth (9) . Some time thereafter, patients develop obstructive lung disease and become colonized with pathogenic microorganisms such as Pseudomonas aeruginosa which leads to respiratory infection and chronic airway inflammation (8) . The end result is severe bronchiectasis and respiratory failure. A recent survey of CF children who underwent bronchoscopy revealed evidence for inflammation (e.g., increased IL-8 in bronchoal-cystic fibrosis; CFTR, CF transmembrane conductance regulator; CTL, cytotoxic T lymphocyte; ORCC, outwardly rectifying CP-channel. veolar lavage [BAL] ) before colonization with pathogenic organisms or onset of clinically overt disease (10) .
Important to the rational development of gene therapy for CF and an assessment of its potential efficacy is an understanding of the underlying pathophysiology of the lung disease. This consideration begins with a description of the molecular and cellular defects in CF. Quinton was the first to note that epithelia from CF patients are relatively impermeable to Cl-, suggesting a primary defect in anion transport (11) . Isolation of the gene responsible for CF spawned a number of studies aimed at defining the function of its protein product and role in ion transport (12) (13) (14) . The 1,480-amino acid open reading frame encoded by this gene has substantial homology to low capacitance transporters such as the multidrug resistance protein, with little structural similarity to known Cl -channels; the protein was therefore named the CF transmembrane conductance regulator (CFTR) (4) . The precise role CFTR has in affecting defects in ion transport found in CF epithelia remains unclear despite extensive biochemical and physiological studies. Analysis of purified CFTR in reconstituted lipid bilayers provided unambiguous evidence that it can function as a chloride channel with unique biochemical properties (linear, cAMP-regulated 8-10 ps Clconductance) (15) . It has become clear, however, that CFTR can also regulate a variety of other cationic and anionic channels. A primary defect in CFTR leads to secondary abnormalities in a number of distinct transport processes including increased absorption of Na+ via the amiloride-sensitive Na+ channel (16) , as well as dysregulation of Cl-secretion through both the protein kinase A-responsive outwardly rectifying Clchannel (ORCC) (17) and the Ca2"-dependent C1-channel (18); each secondary abnormality described to date is reversed by complementation of the primary defect in CFTR. A model for CFTR-mediated regulation of the ORCC was suggested recently by Schwiebert et al., who proposed that CFTR transports ATP to the apical surface where it engages the purinogenic receptor transducing an unknown signal to the ORCC (19) . This complex web of interactions between multiple channels may explain how the relatively nonabundant CFTR protein could have such a profound effect on the function of epithelia. Implications of these findings on gene therapy are discussed below.
Definition of primary cellular defects responsible for CF lung disease has been difficult to discern because of secondary abnormalities that result from the chronic infections established in childhood. One hypothesis is that the defects in ion transport found in epithelia of conducting airway lead to dehydration of mucus, inspissation of secretions, and defective clearance of inhaled pathogens (8) . This elegantly simple hypothesis, however, lacks experimental validation and ignores the complexity of CFTR expression within human lung and the biochemical regulation of the protein. An alternative hypothesis is that the actual macromolecular composition of mucus is perturbed in CF, affecting both its rheologic properties and affinity for microbial pathogens such as pseudomonas. Indeed, previous studies have measured increased sulfation of glycoproteins found in CF mucus (20) . The observation that CFTR functions in intracellular components such as in the endoplasmic reticulum (21) (32) , liposomes (33) , and molecular conjugates (34) . The experience with recombinant adenoviruses in animals and humans is the most advanced and has illustrated principles of in vivo gene therapy for CF. This experience is summarized below.
Human adenoviruses are an attractive vehicle for gene trans- In all models except newborn cotton rat and the human bronchial xenograft, expression of the transgene is transient and associated with a dose-dependent, biphasic, and self-limited inflammatory response. Very little recombinant virus was recovered after gene transfer, except in the bronchial xenograft and in some nonhuman primate studies. The efficiency of gene transfer was diminished in virtually all models after repeated administrations of virus.
Clinical trials have been initiated by six independent groups using a variety of protocols based on nasal and/or lung-directed gene transfer (39) (40) (41) (42) (43) . The goal of these phase I studies is to evaluate safety and efficiency of gene transfer. Protocols based on gene transfer to nasal epithelia provide an excellent opportunity for assessing gene transfer; however, the relevance of the data to intrapulmonary epithelia has been questioned. The major problem with the lung-directed studies is assessment of gene transfer efficiency which requires molecular analyses of bronchial epithelial cells recovered at bronchoscopy; difficulties in obtaining representative samples render negative studies difficult to interpret. Although the data are still preliminary, some interesting trends have emerged. Gene transfer has been documented in lung with -10 plaque forming units (pfu) of virus in both the Cornell/NIH (44) and University of Pennsylvania trials (unpublished data). Nasal epithelia seem much more resistant to gene transfer based on the University of North Carolina trial, which required 10'0 pfu virus to achieve -1% gene transfer (45) . The Iowa/Genzyme group reported partial and transient correction of Cl -transport in nasal epithelia at lower doses of virus (46) , although these studies may have been complicated by injury to the epithelia at the time of virus administration, which could artifactually enhance the efficiency of gene transfer. Preliminary data on the safety of recombinant adenoviruses in humans will be discussed below.
Immunologic barriers to gene therapy
The promise of recombinant adenoviruses for efficient in vivo gene transfer must be buoyed by the consistent problems of inflammation and loss of transgene expression that have characterized their use in virtually all preclinical models, including adult mice (28, (47) (48) (49) , cotton rats (50) (51) (52) (53) (54) , and nonhuman primates (51, (55) (56) (57) (58) (59) . Two the specific immune responses that underlie the observations made in immune-competent animals. We speculated that host responses, which are appropriately mobilized to combat viral pathogens, may be present, albeit in an attenuated way, when recombinant viruses are administered for gene therapy. Principles learned in the field of viral pathogenesis were applied to our studies of adenovirus-mediated gene transfer to lung, a model of which is presented in Fig. 2 .
Identification of virus-specific cytotoxic T lymphocytes (CTLs) as potential immune effectors was suggested initially by in vitro 51Cr release assays. Lymphocytes harvested from BAL and mediastinal lymph nodes of adenovirus-treated C57BL/6 mice were shown to specifically lyse MHC-compatible target cells infected with the recombinant adenovirus (47, 48 (75), the ICP47 gene from herpes simplex virus (76) , and the USH gene from human cytomegalovirus (77) .
Recognition that THi activation is necessary for a fully functional CTL response suggested another therapeutic strategy for avoiding cellular immune responses that extinguish transgene expression. This strategy is based on the premise that THI cells are activated to input virion proteins which are presented by MHC class II but rapidly cleared after the administration of therapy. We reasoned that coadministration of agents that block THi activation with virus should stabilize transgene expression far beyond the period of transient immune blockade. This concept has been validated in mouse models of adenovirus-mediated gene transfer to lung by coadministration of the general cytotoxic drug cyclophosphamide (unpublished data) and the more specific immune modulator anti-CD4 monoclonal antibody (49) . Other potential agents include inhibitors of T cell costimulation (e.g., anti-CD4OL monoclonal antibody [78] or CTLA4-Ig [79] ) and cytokines that inhibit activation of THI cells such as (Fig. 3) . (48, 49, 52) . Unfortunately, more defective viruses will be of little help because the antigenic stimulus for antibody production is capsid proteins of the delivered virus. Strategies described above which attempt to interrupt T helper cell activation to capsid protein at the time of virus delivery, such as cyclophosphamide (unpublished data) and anti-CD4 monoclonal antibody (49), do indeed prevent neutralizing antibody formation and allow successful repeated gene therapy. A more selective strategy was developed based on differential activation of the T helper subsets, THI and TH2, and the role they play in isotype switching. The primary immunoglobulin responsible for neutralization of adenovirus in the airway is IgA which is dependent on TH2 cells for its production (49) . Based on the known cytokine regulation of T helper cell differentiation (Fig. 3) , we developed a strategy to prevent the activation of TH2 cells using IFN-y or IL-12 (which activates THI cells to secrete IFN-y) to inhibit TH2 differentiation (49) . Coadministration of either cytokine at the time of virus instillation did prevent formation of antiviral IgA and allowed efficient readministration of virus. The advantage of this strategy to prevent neutralizing antibody must be balanced, however, with the disadvantage of potentially enhancing CTL-mediated events through activation of THI cells.
Another approach which should be evaluated is to interfere with the molecular interactions of costimulation necessary to activate the CD4 T cells. Examples include CTLA4-Ig (79) and an antibody to CD40 ligand (78) .
Efficacy versus toxicity: therapeutic index
A critical evaluation of any proposed genetic therapy is an assessment of therapeutic index: the dose of vector that provides therapeutic efficacy in the absence of toxicity. Multiple factors will contribute to therapeutic index, including the efficiency and distribution of gene transfer, direct toxic effects of the virus, and antigen-and non-antigen-specific responses of the recipient to the vector and/or genetically modified cell.
Adenoviruses were selected as appropriate vehicles for lungdirected gene therapy because the spectrum of diseases that result from naturally acquired infections (i.e., pharyngitis, upper respiratory infections, and pneumonias) would suggest that the virus is tropic for airway epithelia (35) . Therefore, it is ironic that concerns have been raised about the efficiency with which recombinant adenoviruses transfer genes to airway epithelia (28, 45) . One consistent observation has been that epithelial cells in a fully differentiated epithelium are more resistant to adenovirus-mediated gene therapy than when they are dispersed in culture (28, 80) . Actual in vivo assessments of functional correction in animals and humans have been restricted for technical reasons to nasal epithelia. Very high doses of virus were required to achieve only partial correction of Cl -transport, as measured by mucosal potential difference, in nasal mucosa of CF mice (28) . The experience in nasal epithelia of CF patients has been similarly disappointing (45) .
A Safety concerns with recombinant adenoviruses have focused on replication of the virus and inflammation at the site of therapy with potential systemic consequences. Little is known about the pathogenesis of a naturally acquired adenovirus infection in humans; however, Ginsberg and colleagues have used the cotton rat, which is permissive for replication of AdS in lung, as well as the mouse, which is nonpermissive, as models for human adenovirus pneumonia (82) (83) (84) . A story of pathogenesis has emerged that describes an early non-antigen-specific phase occurring 2-3 d after infection that is cytokine dependent (TNF-a, IL-1, and IL-6) and dominated by polymorphonuclear leukocytes, which is followed by a T celldependent mononuclear-dominated response that is dependent on viral protein expression.
An extensive body of data has accumulated regarding the toxicity associated with administration of El-deleted adenoviruses into the airway of animals. Several consistent findings have emerged from studies performed by multiple investigators in a number of species including mouse, cotton rat, rhesus monkey, and baboon (see Table I ). There is dose-dependent inflammation at the site of gene transfer that diminishes without permanent sequelae. When carefully examined, the response of the recipient resembles the biphasic pathology seen with replication-competent virus in cotton rats, which initially is dominated by neutrophils quickly transitioning into a mononuclear-predominant histology. The pathology noted at necropsy can be detected clinically as an infiltrate on chest radiographs and an increase in lymphocytes in BAL, although the animals have generally tolerated the virus well with few systemic manifestations. There has been little evidence for dissemination and/ or shedding of virus.
Despite extensive work on the immunology of adenovirusmediated gene transfer to lung and the evaluation of a large number of animals in toxicology protocols, little is known about the mechanisms that contribute to the inflammatory responses seen in animals or their relevance in humans. There will likely be at least three components to inflammation seen with higher doses of virus including toxic effects of the virus, non-antigenspecific inflammation to the virus, such as that mediated by NK cells, and antigen-specific activation of T cells (CTL and T helper) and possibly B cells. The fact that administration of inactivated virus is associated with detectable inflammation in the mouse confirms the importance of processes which are independent of virus replication or viral protein expression (85) . The experience with intrapulmonary instillation of virus in patients has been limited but largely unremarkable at the low doses administered to patients. The one patient who received high-dose virus (-109 pfu) is an illustrative exception (44). Within 12 h of administration of virus, she developed fever, hypotension, multilobar infiltrates, and a significant rise in serum IL-6. The intensity and rapidity of onset of this syndrome were not predicted by the animal experiments. This could be explained by species differences or the influence of preexisting immunity to adenoviruses that is endemic in the human population.
Future directions
The development of adenoviral vectors for gene therapy of CF has accelerated the concept of in vivo gene delivery. Lessons learned in the early experiments will likely be generic to in vivo gene therapy with other vectors in different diseases. It is not surprising that host immune responses develop to the vector and genetically corrected cells which try to subvert the therapeutic intervention. A better understanding of host-vector interactions will be essential when designing rational strategies to prevent these confounding problems. Animal studies performed to study these mechanisms primarily have used inbred strains of pathogen-free animals. Predicting effectiveness of therapy in the human population will be more challenging due to substantial heterogeneity in both antigen presentation, based on MHC allelic variation, and the intensity and nature of the immune response, based on previous exposure to adenovirus.
The fact that viral pathogens have evolved strategies to escape immune surveillance (i.e., persistence or latency) should be exploited in the design of second generation therapies. Another approach is to implement adjunctive therapies that modulate the recipients' immune responses to the therapy. Early human pilot experiments that test concepts developed in animal models will be critical in focusing research toward the goal of a cure. This is particularly important when developing strategies to circumvent host responses.
In anticipation of the development of safe and efficient vector systems, the field should prepare for the difficult task of assessing efficacy. The importance of this is reinforced by the likely development of multiple gene transfer technologies in parallel and the need to make early priority decisions. A better understanding of basic pathophysiology of CF with the further development of animal models would be very useful in establishing surrogate endpoints for clinical efficiency. In the absence of such surrogates, important decisions regarding development of effective therapies will defer to phase III trials which are costly and use the most precious resource, which is the pool of patients eligible for clinical trials.
